09:46 AM EST - Antibe Therapeutics Inc. : Has entered into an exclusive licensing agreement with Kwang Dong Pharmaceutical Co., Ltd. for the development and commercialization of Antibe’s lead drug, ATB-346, in South Korea. Kwang Dong is a major pharmaceutical company in the Region, with net sales in excess of $600 million U.S. and over 500 sales representatives. Antibe Therapeutics Inc.
shares V.ATE are trading up $0.06 at $0.34.
